{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:28:20Z","timestamp":1790630900936,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HOMFORexzellent"},{"name":"Chugai Pharma Marketing Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1742-5","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T07:46:33Z","timestamp":1541749593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs"],"prefix":"10.1186","volume":"20","author":[{"given":"David","family":"Schub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"Assmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Sester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-5283","authenticated-orcid":false,"given":"Tina","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"issue":"10","key":"1742_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","volume":"81","author":"BP Yawn","year":"2013","unstructured":"Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81(10):928\u201330.","journal-title":"Neurology"},{"issue":"3","key":"1742_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0961203312470186","volume":"22","author":"EF Chakravarty","year":"2013","unstructured":"Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013;22(3):238\u201344.","journal-title":"Lupus"},{"issue":"10","key":"1742_CR3","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1086\/598331","volume":"48","author":"JR McDonald","year":"2009","unstructured":"McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364\u201371.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1742_CR4","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheum. 2016;68(9):2328\u201337.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1742_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1086\/511274","volume":"195","author":"GN Malavige","year":"2007","unstructured":"Malavige GN, Jones L, Black AP, Ogg GS. Rapid effector function of varicella-zoster virus glycoprotein I-specific CD4+ T cells many decades after primary infection. J Infect Dis. 2007;195(5):660\u20134.","journal-title":"J Infect Dis"},{"issue":"9","key":"1742_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1086\/592219","volume":"198","author":"K Sadaoka","year":"2008","unstructured":"Sadaoka K, Okamoto S, Gomi Y, Tanimoto T, Ishikawa T, Yoshikawa T, et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-\u03b3 enzyme-linked immunospot assay. J Infect Dis. 2008;198(9):1327\u201333.","journal-title":"J Infect Dis"},{"issue":"1","key":"1742_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1086\/421277","volume":"190","author":"MT Vossen","year":"2004","unstructured":"Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW. Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus. J Infect Dis. 2004;190(1):72\u201382.","journal-title":"J Infect Dis"},{"issue":"11","key":"1742_CR8","first-page":"2151","volume":"31","author":"HB Park","year":"2004","unstructured":"Park HB, Kim KC, Park JH, Kang TY, Lee HS, Kim TH, et al. Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol. 2004;31(11):2151\u20135.","journal-title":"J Rheumatol"},{"issue":"11","key":"1742_CR9","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1002\/art.38804","volume":"66","author":"C Rondaan","year":"2014","unstructured":"Rondaan C, de Haan A, Horst G, Hempel JC, van Leer C, Bos NA, et al. Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases. Arthritis Rheum. 2014;66(11):3122\u20138.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1742_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/infdis\/jiu500","volume":"211","author":"D Schub","year":"2015","unstructured":"Schub D, Janssen E, Leyking S, Sester U, Assmann G, Hennes P, et al. Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection. J Infect Dis. 2015;211(4):600\u201312.","journal-title":"J Infect Dis"},{"key":"1742_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13075-016-1176-x","volume":"18","author":"J Humphreys","year":"2016","unstructured":"Humphreys J, Hyrich K, Symmons D. What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? Arthritis Res Ther. 2016;18:282.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1742_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1742_CR13","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.transproceed.2015.09.009","volume":"47","author":"S Leyking","year":"2015","unstructured":"Leyking S, Wolf M, Mihm J, Schaefer M, Bohle RM, Fliser D, et al. Alloreactive T cells to identify risk HLA alleles for retransplantation after acute accelerated steroid-resistant rejection. Transplant Proc. 2015;47(8):2425\u201332.","journal-title":"Transplant Proc"},{"key":"1742_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12967-015-0420-5","volume":"13","author":"S Leyking","year":"2015","unstructured":"Leyking S, Budich K, van Bentum K, Thijssen S, Abdul-Khaliq H, Fliser D, et al. Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients. J Transl Med. 2015;13:51.","journal-title":"J Transl Med"},{"issue":"1","key":"1742_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/eji.201747079","volume":"48","author":"D Schub","year":"2018","unstructured":"Schub D, Fousse M, Fassbender K, Gartner BC, Sester U, Sester M, et al. CTLA-4-expression on VZV-specific T cells in CSF and blood is specifically increased in patients with VZV related central nervous system infections. Eur J Immunol. 2018;48(1):151\u201360.","journal-title":"Eur J Immunol"},{"issue":"6","key":"1742_CR16","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/ajt.12689","volume":"14","author":"T Schmidt","year":"2014","unstructured":"Schmidt T, Adam C, Hirsch HH, Janssen MW, Wolf M, Dirks J, et al. BK polyomavirus-specific cellular immune responses are age-dependent and strongly correlate with phases of virus replication. Am J Transplant. 2014;14(6):1334\u201345.","journal-title":"Am J Transplant"},{"issue":"7","key":"1742_CR17","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/j.1600-6143.2008.02279.x","volume":"8","author":"U Sester","year":"2008","unstructured":"Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant. 2008;8(7):1486\u201397.","journal-title":"Am J Transplant"},{"issue":"3","key":"1742_CR18","doi-asserted-by":"publisher","first-page":"e17813","DOI":"10.1371\/journal.pone.0017813","volume":"6","author":"U Sester","year":"2011","unstructured":"Sester U, Fousse M, Dirks J, Mack U, Prasse A, Singh M, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS One. 2011;6(3):e17813.","journal-title":"PLoS One"},{"issue":"2","key":"1742_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaci.2016.04.013","volume":"138","author":"T Frenz","year":"2016","unstructured":"Frenz T, Grabski E, Buschjager D, Vaas LA, Burgdorf N, Schmidt RE, et al. CD4+ T cells in patients with chronic inflammatory rheumatic disorders show distinct levels of exhaustion. J Allergy Clin Immunol. 2016;138(2):586\u20139 e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1742_CR20","doi-asserted-by":"publisher","first-page":"e014032","DOI":"10.1136\/bmjopen-2016-014032","volume":"7","author":"TL Liao","year":"2017","unstructured":"Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017;7(1):e014032.","journal-title":"BMJ Open"},{"issue":"12","key":"1742_CR21","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.22628","volume":"67","author":"DA Pappas","year":"2015","unstructured":"Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res. 2015;67(12):1671\u20138.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"1742_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2013.1099","volume":"309","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309(9):887\u201395.","journal-title":"JAMA"},{"issue":"5","key":"1742_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/acr.22470","volume":"67","author":"H Yun","year":"2015","unstructured":"Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res. 2015;67(5):731\u20136.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"1742_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/imj.12679","volume":"45","author":"J Segan","year":"2015","unstructured":"Segan J, Staples MP, March L, Lassere M, Chakravarty EF, Buchbinder R. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-\u03b1 inhibitors. Intern Med J. 2015;45(3):310\u20138.","journal-title":"Intern Med J"},{"issue":"9990","key":"1742_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258\u201365.","journal-title":"Lancet"},{"issue":"7","key":"1742_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-\u03b1 agents. JAMA. 2009;301(7):737\u201344.","journal-title":"JAMA"},{"issue":"3","key":"1742_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0166-3542(91)90065-Y","volume":"15","author":"M Ito","year":"1991","unstructured":"Ito M, Nakano T, Kamiya T, Kitamura K, Ihara T, Kamiya H, et al. Effects of tumor necrosis factor \u03b1 on replication of varicella-zoster virus. Antivir Res. 1991;15(3):183\u201392.","journal-title":"Antivir Res"},{"issue":"17","key":"1742_CR28","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1128\/JVI.01149-15","volume":"89","author":"T Whitmer","year":"2015","unstructured":"Whitmer T, Malouli D, Uebelhoer LS, DeFilippis VR, Fruh K, Verweij MC. The ORF61 protein encoded by simian varicella virus and varicella-zoster virus inhibits NF-\u03baB signaling by interfering with I\u03baB\u03b1 degradation. J Virol. 2015;89(17):8687\u2013700.","journal-title":"J Virol"},{"issue":"1","key":"1742_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/annrheumdis-2012-201310","volume":"72","author":"Y Shirota","year":"2013","unstructured":"Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1742_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","volume":"130","author":"O Dienz","year":"2009","unstructured":"Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol. 2009;130(1):27\u201333.","journal-title":"Clin Immunol"},{"key":"1742_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13075-015-0526-4","volume":"17","author":"J Kikuchi","year":"2015","unstructured":"Kikuchi J, Hashizume M, Kaneko Y, Yoshimoto K, Nishina N, Takeuchi T. Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther. 2015;17:10.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1742_CR32","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/art.38107","volume":"65","author":"J Melet","year":"2013","unstructured":"Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013;65(11):2783\u201390.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1742_CR33","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-011-1168-2","volume":"61","author":"D Stroopinsky","year":"2012","unstructured":"Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother. 2012;61(8):1233\u201341.","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"1742_CR34","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352.","journal-title":"N Engl J Med"},{"issue":"10","key":"1742_CR35","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69(10):1960\u20138.","journal-title":"Arthritis Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1742-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1742-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1742-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T19:16:33Z","timestamp":1573240593000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1742-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1742"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1742-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"25 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee (\u00c4rztekammer des Saarlandes no. 158\/13), and all individuals gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"252"}}